Most Clicked StoriesMore >


Novartis may be planning to sell stake in Roche, sources say

BIO SmartBrief | Apr 27, 2016

Sources say Novartis is thinking about divesting its 33.3% stake in Roche, which is valued at almost $14 billion. However, sources say no agreement has been made yet. PharmaTimes (U.K.) (04/26)


Exelixis' kidney cancer drug gets FDA nod

BIO SmartBrief | Apr 26, 2016

TapImmune to collaborate with AstraZeneca on ovarian cancer trial

BIO SmartBrief | Apr 25, 2016

Ironwood acquires rights to AstraZeneca's gout drug

BIO SmartBrief | Apr 28, 2016

FDA fast-tracks bone cancer treatment from Advaxis

BIO SmartBrief | Apr 29, 2016

Stemcentrx to be bought by AbbVie in up-to-$9.8B deal

BIO SmartBrief | Apr 29, 2016

CytomX to develop drug conjugates with AbbVie

BIO SmartBrief | Apr 25, 2016

Head and neck cancer drug from Bristol-Myers wins breakthrough status

BIO SmartBrief | Apr 27, 2016

GlaxoSmithKline to collaborate with Zymeworks on antibody development

BIO SmartBrief | Apr 28, 2016

FDA grants approval to AstraZeneca's COPD therapy

BIO SmartBrief | Apr 27, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Register for BIO's Executive Training Courses

BIO SmartBrief | Apr 29, 2016

BIO survey to support PDUFA 6 negotiations

BIO SmartBrief | Apr 29, 2016

A better way to ship temperature-sensitive materials!

BIO SmartBrief | Apr 28, 2016

Big savings on lab supplies, equipment & chemicals

BIO SmartBrief | Apr 27, 2016

A better way to purchase office supplies and professional printing

BIO SmartBrief | Apr 26, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more